{
  "patient_id": "SB-P008",
  "documents": [
    {
      "visit_number": 1,
      "date": "2025-06-18",
      "type": "progress_note",
      "text": "--- Visit 1 | Date: 2025-06-18 ---\n\nSB-P008 \u2014 Cycle 1, Day 1 visit.\n\nVitals: BP 135/79 mmHg, HR 60 bpm, Weight 72.3 kg.\n\nLaboratory results:\n  - PSA: 12.69 ng/mL [ref 0.0-4.0] (HIGH)\n  - ALT: 2.64 U/L [ref 7.0-56.0] (LOW)\n  - AST: 39.68 U/L [ref 10.0-40.0]\n  - Hemoglobin: 17.65 g/dL [ref 12.0-17.5] (HIGH)\n  - WBC: 5.57 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 0.68 mg/dL [ref 0.7-1.3] (LOW)\n\nAssessment: Tolerating therapy. Plan to continue protocol. Next visit in 3 weeks.\n"
    },
    {
      "visit_number": 2,
      "date": "2025-07-09",
      "type": "progress_note_with_imaging",
      "text": "--- Visit 2 | Date: 2025-07-09 ---\n\nSB-P008 \u2014 Cycle 2, Day 1 visit.\n\nOn exam, BP is 111/82, pulse 87, wt 83.1 kg. Patient appears slightly pale but hemodynamically stable.\n\nRoutine labs obtained:\n  - PSA: 10.55 ng/mL [ref 0.0-4.0] (HIGH)\n  - ALT: 2.16 U/L [ref 7.0-56.0] (LOW)\n  - AST: 43.56 U/L [ref 10.0-40.0] (HIGH)\n  - Hemoglobin: 17.68 g/dL [ref 12.0-17.5] (HIGH)\n  - WBC: 5.5 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 0.65 mg/dL [ref 0.7-1.3] (LOW)\n\nCT shows disease progression \u2014 new lesion identified in the liver. Target measurements also increased (42.6%). RECIST classification: PD.\n\nPSA level is 6.37 ng/mL (increase 42.6% from baseline).\n\nContinue study protocol. Monitor labs. Return visit 3 scheduled in 3 weeks.\n"
    },
    {
      "visit_number": 3,
      "date": "2025-07-30",
      "type": "progress_note",
      "text": "--- Visit 3 | Date: 2025-07-30 ---\n\nFollow-up visit #3 for patient SB-P008.\n\nVS: 170/80 | HR 81 | Wt 75.1 kg. Patient slightly pale but hemodynamically stable.\n\nNo new adverse events reported since last visit.\n\nLaboratory results:\n  - PSA: 11.4 ng/mL [ref 0.0-4.0] (HIGH)\n  - ALT: 4.13 U/L [ref 7.0-56.0] (LOW)\n  - AST: 40.77 U/L [ref 10.0-40.0] (HIGH)\n  - Hemoglobin: 18.01 g/dL [ref 12.0-17.5] (HIGH)\n  - WBC: 5.56 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 0.74 mg/dL [ref 0.7-1.3]\n\nPlan: Continue current dose. Return for cycle 4 in 3 weeks.\n"
    },
    {
      "visit_number": 4,
      "date": "2025-08-20",
      "type": "progress_note_with_imaging",
      "text": "--- Visit 4 | Date: 2025-08-20 ---\n\nFollow-up visit #4 for patient SB-P008.\n\nVitals: BP 117/98 mmHg, HR 67 bpm, Weight 77.1 kg.\n\nRoutine labs obtained:\n  - PSA: 10.54 ng/mL [ref 0.0-4.0] (HIGH)\n  - ALT: 3.61 U/L [ref 7.0-56.0] (LOW)\n  - AST: 43.92 U/L [ref 10.0-40.0] (HIGH)\n  - Hemoglobin: 17.29 g/dL [ref 12.0-17.5]\n  - WBC: 5.01 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 0.75 mg/dL [ref 0.7-1.3]\n\nConcerning findings on restaging: tumor growth of 30.4%. Progressive disease per RECIST criteria.\n\nPSA now 5.82 ng/mL \u2014 increase 30.4% from initial value.\n\nPlan: Continue current regimen. Follow up in 3 weeks.\n"
    },
    {
      "visit_number": 5,
      "date": "2025-09-10",
      "type": "progress_note",
      "text": "--- Visit 5 | Date: 2025-09-10 ---\n\nFollow-up visit #5 for patient SB-P008.\n\nOn exam, BP is 138/62, pulse 93, wt 90.4 kg. Patient appears comfortable, no distress noted.\n\nRoutine labs obtained:\n  - PSA: 9.88 ng/mL [ref 0.0-4.0] (HIGH)\n  - ALT: 9.54 U/L [ref 7.0-56.0]\n  - AST: 42.96 U/L [ref 10.0-40.0] (HIGH)\n  - Hemoglobin: 17.16 g/dL [ref 12.0-17.5]\n  - WBC: 4.33 10^3/uL [ref 4.5-11.0] (LOW)\n  - Creatinine: 0.75 mg/dL [ref 0.7-1.3]\n\nPlan: Monitor closely and reassess at next visit. Return for cycle 6 in 3 weeks.\n"
    },
    {
      "visit_number": 6,
      "date": "2025-10-01",
      "type": "progress_note_with_imaging",
      "text": "--- Visit 6 | Date: 2025-10-01 ---\n\nRoutine protocol visit 6. Patient ID: SB-P008.\n\nVital signs obtained: blood pressure 96/80, heart rate 82, weight 75.5 kg.\n\nBlood work results:\n  - PSA: 9.06 ng/mL [ref 0.0-4.0] (HIGH)\n  - ALT: 3.36 U/L [ref 7.0-56.0] (LOW)\n  - AST: 46.04 U/L [ref 10.0-40.0] (HIGH)\n  - Hemoglobin: 17.18 g/dL [ref 12.0-17.5]\n  - WBC: 4.52 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 0.78 mg/dL [ref 0.7-1.3]\n\nImaging: Target lesion measurements stable \u2014 neither sufficient shrinkage for PR nor increase for PD. Classified as stable disease (SD) per RECIST.\n\nPSA level is 5.08 ng/mL (increase 13.8% from baseline).\n\nContinue study protocol. Monitor labs. Return visit 7 scheduled in 3 weeks.\n"
    },
    {
      "visit_number": 7,
      "date": "2025-10-22",
      "type": "progress_note",
      "text": "--- Visit 7 | Date: 2025-10-22 ---\n\nPatient SB-P008 presents for scheduled cycle 7 visit.\n\nVitals: BP 117/82 mmHg, HR 85 bpm, Weight 82.4 kg.\n\nNo new adverse events reported since last visit.\n\nRoutine labs obtained:\n  - PSA: 9.09 ng/mL [ref 0.0-4.0] (HIGH)\n  - ALT: 5.24 U/L [ref 7.0-56.0] (LOW)\n  - AST: 46.01 U/L [ref 10.0-40.0] (HIGH)\n  - Hemoglobin: 17.11 g/dL [ref 12.0-17.5]\n  - WBC: 4.12 10^3/uL [ref 4.5-11.0] (LOW)\n  - Creatinine: 0.77 mg/dL [ref 0.7-1.3]\n\nAssessment: Tolerating therapy. Plan to continue protocol. Next visit in 3 weeks.\n"
    },
    {
      "visit_number": 8,
      "date": "2025-11-12",
      "type": "progress_note_with_imaging",
      "text": "--- Visit 8 | Date: 2025-11-12 ---\n\nPatient SB-P008 presents for scheduled cycle 8 visit.\n\nOn exam, BP is 148/80, pulse 69, wt 66.1 kg. Patient appears mildly fatigued but alert and oriented.\n\nNew AE: Rash. Severity: mild (Grade 1). Onset: day 164. Resolved by day 170. Relatedness: unlikely. No dose modification required.\n\nLab panel results from today's draw:\n  - PSA: 8.88 ng/mL [ref 0.0-4.0] (HIGH)\n  - ALT: 8.5 U/L [ref 7.0-56.0]\n  - AST: 43.59 U/L [ref 10.0-40.0] (HIGH)\n  - Hemoglobin: 16.94 g/dL [ref 12.0-17.5]\n  - WBC: 4.5 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 0.83 mg/dL [ref 0.7-1.3]\n\nImaging: Target lesion measurements stable \u2014 neither sufficient shrinkage for PR nor increase for PD. Classified as stable disease (SD) per RECIST.\n\nPSA now 3.88 ng/mL \u2014 decrease 13.1% from initial value.\n\nPlan: Continue current regimen. Follow up in 3 weeks.\n"
    }
  ]
}